Trial of Deferiprone in Parkinson’s Disease
- 1 December 2022
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 387 (22), 2045-2055
- https://doi.org/10.1056/nejmoa2209254
Abstract
Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.Keywords
This publication has 23 references indexed in Scilit:
- The role of iron in brain ageing and neurodegenerative disordersThe Lancet Neurology, 2014
- Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's DiseaseAntioxidants and Redox Signaling, 2014
- Regional siderosis: a new challenge for iron chelation therapyFrontiers in Pharmacology, 2013
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's DiseaseThe New England Journal of Medicine, 2009
- Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?Statistics in Medicine, 2009
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing planMovement Disorders, 2007
- Down‐regulation of dopamine transporter by iron chelation in vitro is mediated by altered trafficking, not synthesisJournal of Neurochemistry, 2006
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive ImpairmentJournal of the American Geriatrics Society, 2005
- How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?Movement Disorders, 2003
- Safety profile of the oral iron chelator deferiprone: a multicentre studyBritish Journal of Haematology, 2000